CASE REPORT
Although endovascular stenting has become an option in adults with recurrent or native coarctation, its effects on ventricular function and blood pressure normalization remain controversial. In elderly patients with congenital severe aortic coarctation, the possibility of achieving adequate blood pressure control after coarctation handling is even more dubious.
We report on a 66-year-old female patient referred to our outpatient clinic with a recent diagnosis of severe post-isthmic aortic coarctation. She had a history of surgical ligation of a cerebral aneurysm when she was 25 years old and remained afterwards in good health until the age of 50, when she was diagnosed with idiopathic hypertension and treated medically. In the last 5 years, she had reported difficulties in controlling her blood pressure in spite of maximal medical therapy with calcium channel blockers, bblockers, angiotensin II receptor antagonists and diuretics (amlodipine 10 mg, metoprolol 200 mg, losartan 100 mg, hydrochlorothiazide 50 mg). A 24-hour blood pressure monitoring documented a mean systemic pressure of 160/90 mm Hg with systolic peaks of over 190 mm Hg. Furthermore, she referred exacerbating fatigue and shortness of breath accompanied by dizziness even for mild efforts (NYHA III). A recently performed thoraco-abdominal contrasted CT confirmed the presence of a severe post-isthmic aortic coarctation with well-developed collateralization between the upper body (subclavian and mammary arteries), chest/abdominal wall and lower body arteries (Figure 1a) . Two fungiform aneurysms were also noticed on the right and left border of the aorta and seemed to result from a dilatation of the thoracic collarteral circulation (Figure 1a ). An echocardiography showed a slightly reduced left ventricular function (LVEF 49%, end-diastolic volume 98 ml., end-systolic volume 50 ml., E/A ¼ 0. . A left brachial-left ankle difference in systolic blood pressure of over 70 mm Hg was noticed. Doppler evaluation and invasive measurements confirmed the hemodynamic significance of the coarctation conditioning pre-coarctation hypertension (150 mm Hg systolic) and an invasive peak gradient of around 50 mm Hg.
After collegial discussion and informed consent from the patient, it was decided to percutaneously treat the coarctation, aiming at improving the blood pressure control and relent the rapid evolution of symptoms.
Under general anesthesia and via the left femoral artery, the coarctation was crossed with a coronary guidewire, predilated with a 6-mm angioplasty balloon and finally entered with a balloon expandable covered stent. Under rapid ventricular pacing, a 4.5-cm-long Cheatham platinum (CP) stent was positioned adjacent to the lateral wall of the left subclavian artery and gently dilated within the coarctation so as to reach a 22 mm size. Immediately at the end of the procedure, the cross-coarctation invasive gradient was 5 mm Hg and a control aortography confirmed perfect anchoring of the stent and correction of the coarctation.
In the following days, the patient remained hemodynamically and respiratory stable. Progressive weaning from her antihypertension medications was necessary as a result of mild hypotension (systolic left radial pressure o100 mm Hg) and vertigo during ambulation. She was eventually discharged in the 5th postprocedural day. At 3 weeks from the procedure, she remains asymptomatic and normotensive under therapy with low dose angiotensin converting enzyme inhibitor.
DISCUSSION
Achievement of adequate blood pressure control after treatment of aortic coarctation remains controversial. Although preoperative hypertension normally regresses after successful repair of coarctation, the rate of patients with normal pressure seems to fall at long-term follow-up. 1 In fact, in patients with repaired coarctation, reduced vascular reactivity seems to be associated with persistence of hypertension, which is an important predictor for late morbidity and mortality. 2 Diagnosis of congenital aortic coarctation in advanced age is rare. In this occasion, indication to invasive treatment should be timely pondered and procedure risks may overcome its possible benefits. When maximal medical therapy does not suffice and symptoms are exacerbating, percutaneous treatment may represent the only alternative.
In the case herein reported, in spite of the advanced age, the patient did not appear to have developed any end-stage organ failure and her left ventricular function and structure were slightly altered. We were well aware of the possible unresponsiveness of such an inveterate systemic hypertension. In reality, a percutaneous attempt at handling the coarctation was deemed to be worthwhile and at a containable procedural risk. In fact, in spite of the tight coarctation and tortuosity of the aorta, lack of thick calcifications at the level of the lesion suggested a preserved elasticity of the aortic tissue.
Although we present just immediate and short term follow-up data, systemic blood pressure was normalized acutely and remained well controlled in the following weeks with a very much reduced pharmacological intake.
To our knowledge, this is the first report of percutaneous handling of a congenital aortic coarctation at such an adult age.
Our experience could suggest a more aggressive treatment of symptomatic aortic coarctation even in patients with more advanced age and whenever the anatomy of the lesion seems amenable to a percutaneous approach.
Long-term follow-up data will be necessary to consolidate the success of the procedure and confirm the persistence in arterial blood pressure reduction. 1 published an interesting review in this journal on the relevance of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) for hypertensive disorders of pregnancy (HDP) and its complications. They have concluded that failure of regulation of the MMP/TIMP system in controlling the extracellular matrix remodeling may lead to diverse pathology, such as gestational hypertension (GH) and preeclampsia (PE). We would like to contribute additional, supportive data regarding plasma and genetic alterations in the MMP/TIMP system in HDP [2] [3] [4] ( Table 1) .
Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs genetic polymorphisms and plasma levels in hypertensive disorders of pregnancy
Higher MMP-9 levels in GH 2 are in agreement with our prior findings reporting elevated pro-MMP-9 in women with GH. 5 Moreover, higher TIMP-1 levels were observed in GH and PE. 2 However, no significant differences were observed in MMP-9/ TIMP-1 ratios. 2 Conversely, while we have not previously found significant differences in pro-MMP-2 and TIMP-2 levels in HDP, 5 we recently reported higher MMP-2 and TIMP-2 concentrations in women with PE, but there were no differences in MMP-2/TIMP-2 ratios.
3 In addition, we reported higher MMP-2 levels and MMP-2/ TIMP-2 ratios in GH. 3 Importantly, different methods may be used to assess MMP and TIMP levels, as highlighted by Karthikeyan et al. 1 Although we have previously evaluated MMP activity by zymography, 5 we have recently performed enzyme-linked immunosorbent assays (ELISAs) to measure plasma MMP-9 2 and MMP-2 3 levels. Moreover, ELISA from different brands may detect distinct TIMP epitopes. 2, 3, 5 Although differences among studies may rely on different detection methods, they could also be due to differences in the gestational age at sampling (Table 1) , as studies have observed changes in MMP-2 and MMP-9 levels throughout gestation. 6, 7 Interestingly, many reports have shown that the C-1562T (rs3918242) and À 90(CA) 13-25 (rs2234681) polymorphisms in the MMP-9 promoter, and the C-1306T (rs243865) and C-735T (rs2285053) polymorphisms in the MMP-2 promoter may affect gene and protein expressions of MMP-9 and MMP-2, respectively. As MMP activity can be regulated transcriptionally, we have investigated the role of these functional genetic polymorphisms of MMPs in HDP. [2] [3] [4] We reported that the CT genotype and T allele for the C-1562T polymorphism were more commonly found in GH, but not in PE, compared with healthy pregnant women, suggesting that this polymorphism is associated only with GH. 4 We also found evidence that genetic variants for the À 90(CA) 13-25 polymorphism may affect plasma MMP-9 concentrations and MMP-9/TIMP-1 ratios in GH.
2 MMP-2 genetic variations of the C-1306T and C-735T polymorphisms were also associated with altered plasma MMP-2 and TIMP-2 concentrations in PE. 3 We have also recently characterized interactions between MMP-9 and VEGF genotypes that were associated with PE, 8 but not with GH; however, these interactions did not affect plasma MMP-9 levels in HDP. 9 Given the importance of circulating MMPs and TIMPs in hypertension, 10 we expect that further epistasis analysis including MMP and TIMP polymorphisms may explain MMP/TIMP ratios.
In summary, the findings cited here may contribute to the review of Karthikeyan et al. 1 and with additional relevant information to HDP susceptibility.
